These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 28488218)

  • 1. Discovery of Therapeutic Lead Molecule Against β-Tubulin Using Computational Approach.
    Ramanathan K; Verma K; Gupta N; Shanthi V
    Interdiscip Sci; 2018 Dec; 10(4):734-747. PubMed ID: 28488218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring β-Tubulin Inhibitors from Plant Origin using Computational Approach.
    Verma K; Kannan K; V S; R S; V K; K R
    Phytochem Anal; 2017 May; 28(3):230-241. PubMed ID: 28008675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of Paclitaxel Resistant R306C Mutation in β-Tubulin—A Computational Approach.
    Verma K; Ramanathan K
    J Cell Biochem; 2015 Jul; 116(7):1318-24. PubMed ID: 25735511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular dynamics simulation and free energy landscape methods in probing L215H, L217R and L225M βI-tubulin mutations causing paclitaxel resistance in cancer cells.
    Tripathi S; Srivastava G; Sharma A
    Biochem Biophys Res Commun; 2016 Aug; 476(4):273-279. PubMed ID: 27233604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the impact of F270V mutation in the β-tubulin (Bos Taurus) structure and its function: a computational perspective.
    Verma K; Ramanathan K
    Biotechnol Lett; 2015 May; 37(5):1003-11. PubMed ID: 25631779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effect of the chiral centers of Taxol on binding to β-tubulin: A docking and molecular dynamics simulation study.
    Ghadari R; Alavi FS; Zahedi M
    Comput Biol Chem; 2015 Jun; 56():33-40. PubMed ID: 25854803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural insight into the mechanism of epothilone A bound to beta-tubulin and its mutants at Arg282Gln and Thr274Ile.
    Shi G; Wang Y; Jin Y; Chi S; Shi Q; Ge M; Wang S; Zhang X; Xu S
    J Biomol Struct Dyn; 2012; 30(5):559-73. PubMed ID: 22731768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
    Mukhtar E; Adhami VM; Sechi M; Mukhtar H
    Cancer Lett; 2015 Oct; 367(2):173-83. PubMed ID: 26235140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
    Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
    Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel tubulin inhibitors via structure-based hierarchical virtual screening.
    Cao R; Liu M; Yin M; Liu Q; Wang Y; Huang N
    J Chem Inf Model; 2012 Oct; 52(10):2730-40. PubMed ID: 22992059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A molecular docking study of anticancer drug paclitaxel and its analogues.
    Sinha R; Vidyarthi AS; Shankaracharya
    Indian J Biochem Biophys; 2011 Apr; 48(2):101-5. PubMed ID: 21682141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ferrocenyl Paclitaxel and Docetaxel Derivatives: Impact of an Organometallic Moiety on the Mode of Action of Taxanes.
    Wieczorek A; Błauż A; Żal A; Arabshahi HJ; Reynisson J; Hartinger CG; Rychlik B; Plażuk D
    Chemistry; 2016 Aug; 22(32):11413-21. PubMed ID: 27376707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The betaI/betaIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies.
    Magnani M; Ortuso F; Soro S; Alcaro S; Tramontano A; Botta M
    FEBS J; 2006 Jul; 273(14):3301-10. PubMed ID: 16803461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidating the mechanism of action of the clinically approved taxanes: a comprehensive comparison of local and allosteric effects.
    Churchill CD; Klobukowski M; Tuszynski JA
    Chem Biol Drug Des; 2015 Nov; 86(5):1253-66. PubMed ID: 26032329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclostreptin (FR182877), an antitumor tubulin-polymerizing agent deficient in enhancing tubulin assembly despite its high affinity for the taxoid site.
    Edler MC; Buey RM; Gussio R; Marcus AI; Vanderwal CD; Sorensen EJ; Díaz JF; Giannakakou P; Hamel E
    Biochemistry; 2005 Aug; 44(34):11525-38. PubMed ID: 16114889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural investigations into the binding mode of novel neolignans Cmp10 and Cmp19 microtubule stabilizers by in silico molecular docking, molecular dynamics, and binding free energy calculations.
    Tripathi S; Kumar A; Kumar BS; Negi AS; Sharma A
    J Biomol Struct Dyn; 2016 Jun; 34(6):1232-40. PubMed ID: 26212016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
    Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of the tubulin bound paclitaxel conformation for structure-based rational drug design.
    Geney R; Sun L; Pera P; Bernacki RJ; Xia S; Horwitz SB; Simmerling CL; Ojima I
    Chem Biol; 2005 Mar; 12(3):339-48. PubMed ID: 15797218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
    Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
    J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and in vitro Biological Evaluation of Ferrocenyl Side-Chain-Functionalized Paclitaxel Derivatives.
    Plażuk D; Wieczorek A; Ciszewski WM; Kowalczyk K; Błauż A; Pawlędzio S; Makal A; Eurtivong C; Arabshahi HJ; Reynisson J; Hartinger CG; Rychlik B
    ChemMedChem; 2017 Nov; 12(22):1882-1892. PubMed ID: 28941201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.